Key Takeaways GLP-1 users are much more likely to experience nail detachment or discoloration than people not on the ...

Eli Lilly's experimental obesity drug combination has delivered weight loss of up to 23.3% in a mid-stage trial, adding to ...

MassHealth dropped GLP-1 weight loss drug coverage in the fiscal 2027 budget, and in February, the Group Insurance Commission ...

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) ...

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, ...

Two Indian nationals have been indicted in the US over the smuggling and selling of fake Ozempic drugs, raising concerns ...

A recent study published in Pediatrics found that the use of GLP-1 medications among young children with obesity in the United States remains rare but has increased.

In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the ...

Two new studies of a GLP-1 drugs that help manage diabetes found that some patients lost 25% of their body weight.

Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ...

Quoting his father’s views about medical injustice, Martin Luther King III cautioned that the state’s decisions to stop ...

High monthly costs lead to over 80% of weight loss patients to stop taking GLP-1 medications. University of Georgia research found patients hit a sharp drop-off when monthly bills exceed $75.